NICE backs Strensiq for some HPP patients

The U.K.'s NICE issued draft guidance recommending approval of Strensiq asfotase alfa from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat the bone manifestations of perinatal- and infantile-onset hypophosphatasia as part of a managed access agreement.

The recommendation covers patients whose onset of the disease occurs before six months of age. The drug is approved in Europe for that population as well as juvenile-onset HPP, which includes patients with disease onset prior to 18 years of age. ...